Cost-effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis

Published in: Clinical Therapeutics, v. 34, no. 5, May 2012, p. 1132-1144

Posted on on May 01, 2012

by John P. Caloyeras, Bin Zhang, Cheng Wang, Marianne Eriksson, Sten Fredrikson, Karola Beckmann, Volker Knappertz, Christoph Pohl, Hans-Peter Hartung, Dhvani Shah, Jeffrey D Miller, Rupert Sandbrink, Vivian Lanius, Kathleen Gondek, Mason W Russell

Read More

Access further information on this document at Clinical Therapeutics

This article was published outside of RAND. The full text of the article can be found at the link above.

OBJECTIVES: To assess, from a Swedish societal perspective, the cost effectiveness of interferon β-1b (IFNB-1b) after an initial clinical event suggestive of multiple sclerosis (MS) (ie, early treatment) compared with treatment after onset of clinically definite MS (CDMS) (ie, delayed treatment). METHODS: A Markov model was developed, using patient level data from the BENEFIT trial and published literature, to estimate health outcomes and costs associated with IFNB-1b for hypothetical cohorts of patients after an initial clinical event suggestive of MS. Health states were defined by Kurtzke Expanded Disability Status Scale (EDSS) scores. Model outcomes included quality-adjusted life years (QALYs), total costs (including both direct and indirect costs), and incremental cost-effectiveness ratios. Sensitivity analyses were performed on key model parameters to assess the robustness of model results. RESULTS: In the base case scenario, early IFNB-1b treatment was economically dominant (ie, less costly and more effective) versus delayed IFNB-1b treatment when QALYs were used as the effectiveness metric. Sensitivity analyses showed that the cost-effectiveness results were sensitive to model time horizon. Compared with the delayed treatment strategy, early treatment of MS was also associated with delayed EDSS progressions, prolonged time to CDMS diagnosis, and a reduction in frequency of relapse. CONCLUSION: Early treatment with IFNB-1b for a first clinical event suggestive of MS was found to improve patient outcomes while controlling costs.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.